{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_6924", "batch_size": 200, "batch_pos": 75, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment uses neutral/positive/factual language ('advantages', 'efficacy', 'speed', 'scalability', 'reliability', 'addressing', 'outbreaks', 'demonstrated') without high-potency verbs or metaphors.", "method": "llm_batch", "batch_id": "batch_2_17616", "batch_size": 200, "batch_pos": 65, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"hop_idx": 3, "answer": "uncertain", "rationale": "Missing response from batch", "method": "fallback", "batch_id": "batch_3_12948", "batch_size": 200, "batch_pos": 36, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The segment lists advantages but does not use a moderate verb paired with scale or impact.", "method": "llm_batch_retry", "retry": 1, "batch_id": "batch_3_12948_r1", "batch_size": 200, "batch_pos": 36, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "Segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_19880", "batch_size": 200, "batch_pos": 33, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "The segment describes advantages of vaccine technology but contains no explicit calming language about the current situation.", "method": "llm_batch", "batch_id": "batch_5_14768", "batch_size": 200, "batch_pos": 32, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "No minimiser token ('only', 'just', 'merely', etc.) combined with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_17168", "batch_size": 200, "batch_pos": 14, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_14652", "batch_size": 200, "batch_pos": 198, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "The segment mentions 'technology offers advantages in efficacy, speed of development and production' which describes capability/development without calming keywords.", "method": "llm_batch", "batch_id": "batch_8_19220", "batch_size": 200, "batch_pos": 117, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
